Skip to main content
. 2015 Jul 14;23(9):1444–1455. doi: 10.1038/mt.2015.112

Figure 8.

Figure 8

The combination of 4Mu + Cy + AdIL-12 modulates the expression of proangiogenic and antiangiogenic factors. (a) Quantification of serum VEGF by enzyme-linked immunosorbent assay (ELISA) at day 14. ***P < 0.001: control versus 4Mu + Cy + AdIL-12, Kruskal-Wallis test. (b) Quantification of VEGF in tumor samples by ELISA at day 14. **P < 0.01: control versus 4Mu + Cy + AdIL-12, Kruskal-Wallis test. (c) Intratumoral mRNA levels of VEGF, HIF1-α, IL-6, TSP-1, and IP-10 by real-time polymerase chain reaction at day 14. VEGF: *P < 0.05: control versus 4Mu; ***P < 0.001: control versus 4Mu + Cy + AdIL-12; IL6: *P < 0.05: control versus 4Mu + Cy + AdIL-12; HIF1-α: ***P < 0.001: control versus 4Mu + Cy + AdIL-12; control versus Cy + AdIL-12 and control versus 4Mu; IP-10: *P < 0.05: control versus Cy + AdIL-12, ***P < 0.001: control versus 4Mu + Cy + AdIL-12; TSP-1: *P < 0.05: control versus 4Mu, control versus Cy + AdIL-12 and control versus 4Mu + Cy + AdIL-12. Kruskal-Wallis test. Bars represent the average of measures of each group (n = 6/group) ± SEM. Experiments are shown as the representative of two independent assays.